450 related articles for article (PubMed ID: 29769207)
1. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
[No Abstract] [Full Text] [Related]
2. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
3. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
4. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.
Luo X; Donnelly CR; Gong W; Heath BR; Hao Y; Donnelly LA; Moghbeli T; Tan YS; Lin X; Bellile E; Kansy BA; Carey TE; Brenner JC; Cheng L; Polverini PJ; Morgan MA; Wen H; Prince ME; Ferris RL; Xie Y; Young S; Wolf GT; Chen Q; Lei YL
J Clin Invest; 2020 Apr; 130(4):1635-1652. PubMed ID: 31874109
[TBL] [Abstract][Full Text] [Related]
5. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
6. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
8. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
9. The impact of LncRNA-SOX2-OT/let-7c-3p/SKP2 Axis on head and neck squamous cell carcinoma progression: Insights from bioinformatics analysis and experimental validation.
Wang D; Zhao X; Li S; Guo H; Li S; Yu D
Cell Signal; 2024 Mar; 115():111018. PubMed ID: 38110167
[TBL] [Abstract][Full Text] [Related]
10. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
Front Immunol; 2021; 12():763086. PubMed ID: 34733290
[TBL] [Abstract][Full Text] [Related]
11. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
12. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma.
Xie G; Shan L; Yang C; Liu Y; Pang X; Teng S; Wu TC; Gu X
Sci Rep; 2023 Oct; 13(1):18476. PubMed ID: 37898690
[TBL] [Abstract][Full Text] [Related]
15. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
16. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
17. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
Front Immunol; 2019; 10():1206. PubMed ID: 31214178
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
20. Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Ye G; Zhang J; Zhang C
Aging (Albany NY); 2021 Aug; 13(16):20793-20807. PubMed ID: 34459788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
